Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Up 0.7% – What’s Next?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) shares traded up 0.7% during trading on Friday . The stock traded as high as $10.48 and last traded at $10.48. Approximately 800 shares changed hands during trading, a decline of 82% from the average session volume of 4,443 shares. The stock had previously closed at $10.41.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $20.00.

Telix Pharmaceuticals Trading Up 0.7%

The stock’s fifty day simple moving average is $10.17 and its 200-day simple moving average is $9.03.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.